Denali Therapeutics Gains Momentum Ahead of Key Rare Disease Data Presentations
Denali Therapeutics (DNLI) shares have surged nearly 50% in three months as the biotech firm prepares to unveil new clinical data for its Enzyme Transport Vehicle platform at the upcoming WORLDSymposium. Investors are weighing whether the recent rally has fully priced in the pipeline's potential.